H.R. 7667 · 117th Congress

Food and Drug Amendments of 2022

Introduced on May 6, 2022 by Anna G. Eshoo (D-CA-18). 3 cosponsors, 2 of them from another party. Latest action (Jun 9, 2022): Received in the Senate.

Stage
Passed one chamber
Introduced
May 6, 2022
Cosponsors
3
2 from the other party
Policy area
Health
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. Reported by committee
  3. Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.

Subjects

  • Advanced technology and technological innovations
  • Advisory bodies
  • Animal protection and human-animal relationships
  • Blood and blood diseases
  • Business records
  • Cardiovascular and respiratory health
  • Child health
  • Computer security and identity theft
  • Congressional oversight
  • Criminal investigation, prosecution, interrogation
  • Department of Health and Human Services
  • Drug safety, medical device, and laboratory regulation
  • Emergency medical services and trauma care
  • Employee hiring
  • Evidence and witnesses
  • Executive agency funding and structure
  • Food and Drug Administration (FDA)
  • Genetics
  • Government employee pay, benefits, personnel management
  • Government information and archives
  • Government studies and investigations
  • Health care coverage and access
  • Health programs administration and funding
  • Health technology, devices, supplies
  • Industrial facilities
  • Infectious and parasitic diseases
  • Inflation and prices
  • Licensing and registrations
  • Manufacturing
  • Marketing and advertising
  • Medical research
  • Minority health
  • Musculoskeletal and skin diseases
  • Organ and tissue donation and transplantation
  • Performance measurement
  • Photography and imaging
  • Prescription drugs
  • Product development and innovation
  • Public participation and lobbying
  • Public-private cooperation
  • Radiation
  • Research and development
  • Small business
  • User charges and fees

Summary

By the Congressional Research Service (Passed House, Jun 8, 2022). Public domain.

Food and Drug Amendments of 2022

This bill reauthorizes Food and Drug Administration (FDA) user fee programs for certain drugs and devices, establishes requirements to increase diversity in clinical trials, and modifies requirements relating to the overall supply chain for drugs and devices.

Specifically, the bill reauthorizes through FY2027 the FDA user fee programs for prescription drugs, medical devices, generic drugs, and biosimilars.

The bill also requires the development of action plans and related reporting to increase the diversity of participants in clinical trials.

In addition, the bill requires the FDA to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).

The bill also (1) establishes requirements and reauthorizes programs to support the development of specific categories of drugs and devices (e.g., pediatric drugs) and inspections of drug manufacturing facilities; and (2) establishes and revises requirements relating to the approval of drugs and devices, including requirements for postapproval studies and guidance about using real-world evidence to support drug and device applications.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Anna G. EshooD-CA-18Sponsor

Democrats · 1

Republicans · 2

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

  1. On Motion to Suspend the Rules and Pass, as Amended
    Jun 8, 2022· House· Passage· Passed 392–28

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. May 6, 2022Introduced in House
  2. May 6, 2022Introduced in House
  3. May 6, 2022 · HouseReferred to the House Committee on Energy and Commerce.
  4. May 9, 2022 · HouseReferred to the Subcommittee on Health.
  5. May 11, 2022 · HouseSubcommittee Consideration and Mark-up Session Held.
  6. May 11, 2022 · HouseForwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 30 - 0 .
  7. May 18, 2022 · HouseCommittee Consideration and Mark-up Session Held.
  8. May 18, 2022 · HouseOrdered to be Reported (Amended) by the Yeas and Nays: 55 - 0.
  9. Jun 7, 2022Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-348.
  10. Jun 7, 2022 · HouseReported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-348.
  11. Jun 7, 2022 · HousePlaced on the Union Calendar, Calendar No. 262.
  12. Jun 7, 2022 · HouseMr. Pallone moved to suspend the rules and pass the bill, as amended.
  13. Jun 7, 2022 · HouseConsidered under suspension of the rules. (consideration: CR H5298-5321)
  14. Jun 7, 2022 · HouseDEBATE - The House proceeded with forty minutes of debate on H.R. 7667.
  15. Jun 7, 2022 · HouseAt the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
  16. Jun 8, 2022 · HouseConsidered as unfinished business. (consideration: CR H5402-5403)
  17. Jun 8, 2022Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 392 - 28 (Roll no. 254).House · Roll call 254
  18. Jun 8, 2022 · HouseOn motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 392 - 28 (Roll no. 254). (text: 06/07/2022 CR H5298-5319)House · Roll call 254
  19. Jun 8, 2022 · HouseMotion to reconsider laid on the table Agreed to without objection.
  20. Jun 9, 2022 · SenateReceived in the Senate.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. AMERICAN FOREST & PAPER ASSOCIATION2 reports
    $1.6M reported (all issues)

Reports filed in 2023, 2024.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 8, 2026 · loaded Oct 8, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 7, 2026 · loaded Oct 7, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.